Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics has announced a strategic partnership with Fisher Healthcare, part of Thermo Fisher Scientific, to distribute its rapid respiratory test, FebriDx®, in the United States. The FDA-cleared FebriDx® test delivers results in 10 minutes from a fingerstick blood sample, aiding in the diagnosis of bacterial acute respiratory infections. This collaboration aims to leverage Fisher Healthcare’s network to enhance the availability of FebriDx® across various healthcare settings in the US.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
